Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - NSCLC metastatic 2

LBA54 - Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC

Date

21 Sep 2020

Session

Proffered Paper - NSCLC metastatic 2

Topics

Immunotherapy;  Non-Small Cell Lung Cancer

Presenters

Jong-Seok Lee

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

J. Lee1, S. Sugawara2, J.H. Kang3, H.R. Kim4, N. Inui5, T. Hida6, K.H. Lee7, T. Yoshida8, H. Tanaka9, C.T. Yang10, M. Nishio11, Y. Ohe8, T. Tamura12, N. Yamamoto13, C. Yu14, H. Akamatsu13, Y. Namba15, N. Sumiyoshi16, K. Nakagawa17

Author affiliations

  • 1 Division Of Hematology And Medical Oncology, Department Of Internal Medicine, Seoul National University Bundang Hospital, 13620 - Gyeonggi-do/KR
  • 2 Department Of Pulmonary Medicine, Sendai Kousei Hospital, 980-0873 - Miyagi/JP
  • 3 Department Of Medical Oncology, The Catholic University of Korea, Seoul St. Mary’s Hospital, 06591 - Seoul/KR
  • 4 Division Of Medical Oncology, Department Of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 5 Department Of Pulmonary Medicine, Hamamatsu University Hospital, 431-3192 - Shizuoka/JP
  • 6 Department Of Thoracic Oncology, Aichi Cancer Center, 464-8681 - Aichi/JP
  • 7 Department Of Internal Medicine, Chungbuk National University Hospital, 28644 - Chungcheongbuk-do/KR
  • 8 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 9 Department Of Internal Medicine, Niigata Cancer Center Hospital, 951-8566 - Niigata/JP
  • 10 Department Of Thoracic Medicine, Chang Gung Memorial Hospital, 33305 - Taoyuan/TW
  • 11 Department Of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 12 Thoracic Center, St. Luke's International Hospital, 104-8560 - Tokyo/JP
  • 13 Internal Medicine Iii, Wakayama Medical University, 641-8509 - Wakayama/JP
  • 14 Department Of Internal Medicine, National Taiwan University Hospital, 10002 - Taipei/TW
  • 15 Clinical Science, Ono Pharmaceutical Co., Ltd., 541-8564 - Osaka/JP
  • 16 Oncology Clinical Development Planning 1, Ono Pharmaceutical Co., Ltd., 541-8564 - Osaka/JP
  • 17 Department Of Medical Oncology, Kindai University Faculty of Medicine, 589-8511 - Osaka/JP
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA54

Background

Nivolumab has been approved as second or later line therapy for NSCLC. It is becoming evident that cytotoxic chemotherapy and angiogenesis inhibitors may enhance therapeutic benefits of immune checkpoint inhibitors such as nivolumab. ONO-4538-52/TASUKI-52 is the first randomized, double-blinded phase III trial of nivolumab plus platinum chemotherapy with bevacizumab for first-line treatment of non-squamous NSCLC.

Methods

Between May 2017 and June 2019, treatment-naïve stage IIIB/IV or recurrent nsq NSCLC patients without sensitizing EGFR or ALK alterations were randomized 1:1 to receive nivolumab (360 mg) or placebo in combination with carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) every 3 weeks for up to 6 cycles. Subsequently, the treatments with nivolumab/placebo and bevacizumab were maintained until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) assessed by the independent radiology review committee (IRRC).

Results

Of 550 patients in Japan, Korea, and Taiwan, and 273 (nivolumab) and 275 (placebo) received ≥ 1 dose of the study drugs. At the interim analysis on July 2020 where the median follow-up was 13.7 months, PFS was significantly longer in the nivolumab arm compared to the placebo arm with the median PFS of 12.12 vs 8.11 months (hazard ratio [HR], 0.56; 96.37% CI, 0.43-0.71; p<0.0001) and 12-month PFS rate of 50.1% vs 30.2%. IRRC assessed Objective response rates were 61.5% and 50.5% in the nivolumab and placebo arms, respectively. OS, while not mature, tended to be longer in the nivolumab arm compared to the placebo arm (HR, 0.85; 95% CI, 0.63-1.14). Treatment-related adverse events (TRAEs) with grade 3 or 4 and TRAEs leading to treatment discontinuation were observed in 73.6% and 16.5% in the nivolumab arm and 72.0% and 4.4% in the placebo arm, respectively. Most frequently-observed TRAEs were alopecia, peripheral sensory neuropathy, and decreased neutrophil count.

Conclusions

ONO-4538-52/TASUKI-52 met the primary endpoint; nivolumab in combination with carboplatin, paclitaxel, and bevacizumab significantly prolonged PFS with a manageable safety profile.

Clinical trial identification

NCT03117049.

Editorial acknowledgement

Legal entity responsible for the study

Ono Pharmaceutical Co., Ltd.

Funding

Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb.

Disclosure

J-S. Lee: Research grant/Funding (institution): Ono Pharmaceutical. S. Sugawara: Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): MSD; Honoraria (self): Chugai Pharma; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Pfizer; Honoraria (self): Eli Lilly and Company; Honoraria (self): Novartis; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): AstraZeneca. J.H. Kang: Research grant/Funding (institution): Ono Pharmaceutical. H.R. Kim: Research grant/Funding (institution): Ono Pharmaceutical. N. Inui: Honoraria (self): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): Taiho Pharmaceutical Co., Ltd; Honoraria (self), Research grant/Funding (institution): MSD K.K; Honoraria (self), Research grant/Funding (institution): Chugai Pharmaceutical Co., Ltd; Honoraria (self), Research grant/Funding (institution): Novarits Japan; Research grant/Funding (institution): Daiichi Sankyo Company, Ltd; Honoraria (self), Research grant/Funding (institution): Eli Lilly Japan K.K; Honoraria (self), Research grant/Funding (institution): Nippon Boehringer Ingelheim Co., Ltd; Honoraria (self): AstraZeneca K.K. T. Hida: Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): Chugai Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Nippon Boehringer Ingelheim; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (institution): Bristol-Meyers Squibb; Honoraria (self), Research grant/Funding (institution): Kissei; Honoraria (self), Research grant/Funding (institution): Taiho Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Takeda Pharmaceutical Co., Ltd.; Research grant/Funding (institution): Ignyta; Research grant/Funding (institution): Merck Serono; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): Janssen Pharmaceutical; Honoraria (self), Research grant/Funding (institution): AstraZeneca. K.H. Lee: Research grant/Funding (institution): Ono Pharmaceutical. T. Yoshida: Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Takeda; Honoraria (self): Chugai; Honoraria (self): Novartis; Research grant/Funding (institution): MSD; Research grant/Funding (institution): AbbVie. H. Tanaka: Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (institution): Eli Lilly; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Taiho Pharmaceutical; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self), Research grant/Funding (institution): Chugai pharmaceutical; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Travel/Accommodation/Expenses: Boehringer Ingelheim. C.T. Yang: Honoraria (self): Ono Pharmaceutical; Honoraria (self): MSD; Honoraria (self): Pfizer; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Roche; Honoraria (self): Chugai. M. Nishio: Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): Bristol Myers Squibb; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self), Research grant/Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant/Funding (institution): Eli Lilly; Honoraria (self), Research grant/Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self): Boehringer-Ingelheim; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self): Merck Biopharma; Honoraria (self), Research grant/Funding (institution): Daiichi Sankyo; Honoraria (self), Research grant/Funding (institution): Takeda Pharmaceutical Company Limited; Honoraria (self): Teijin Pharma Limited.; Honoraria (self): AbbVie. Y. Ohe: Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self): Boehringer Ingelheim; Honoraria (self), Research grant/Funding (institution): Chugai; Honoraria (self), Research grant/Funding (institution): Eli Lilly; Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self), Research grant/Funding (institution): Takeda; Honoraria (self), Research grant/Funding (institution): Nippon Kayaku; Honoraria (self), Research grant/Funding (institution): Kyorin; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (institution): Janssen; Honoraria (self): Pfizer; Research grant/Funding (institution): Ignyta; Research grant/Funding (institution): Kyowa Hakko Kirin; Honoraria (self): Celtrion; Honoraria (self): Amgen. T. Tamura: Research grant/Funding (institution): Ono Pharmaceutical; Honoraria (self): Chugai Pharmaceutical; Honoraria (self): Lilly. N. Yamamoto: Honoraria (self), Research grant/Funding (institution): Ono Pharmaceutical; Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self): Thermo Fisher Scientific; Honoraria (self), Research grant/Funding (institution): Daiichi-Sankyo; Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self): Takeda; Honoraria (self), Research grant/Funding (institution): Chugai; Honoraria (self), Research grant/Funding (institution): Eli Lilly Japan; Honoraria (self), Research grant/Funding (institution): Boehringer-Ingelheim; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Novartis; Honoraria (self): Nipponkayaku; Research grant/Funding (institution): Shionogi; Research grant/Funding (institution): Tsumura; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): Terumo; Research grant/Funding (institution): Tosoh; Research grant/Funding (institution): Toppan Printing. C-J. Yu: Research grant/Funding (institution): Ono Pharmaceutical. H. Akamatsu: Honoraria (self): Ono Pharmaceutical; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Chugai Pharmatheutical; Honoraria (self): Astrazeneca; Honoraria (self): Bristol-Myers Squibb. Y. Namba: Full/Part-time employment: Ono Pharmaceutical. N. Sumiyoshi: Full/Part-time employment: Ono Pharmaceutical. K. Nakagawa: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Ono Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Astellas Pharma Inc.; Honoraria (self), Research grant/Funding (institution): MSD K.K.; Honoraria (self), Research grant/Funding (institution): Nippon Boehringer Ingelheim Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Novartis Pharma K.K.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer Japan Inc.; Honoraria (self), Research grant/Funding (institution): Bristol Myers Squibb Company; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly Japan K.K.; Honoraria (self), Research grant/Funding (institution): Chugai Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Daiichi Sankyo Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Merck Serono Co., Ltd./ Merck Biopharma Co., Ltd.; Honoraria (self): Clinical Trial Co., Ltd.; Honoraria (self): Medicus Shuppan, Publishers Co., Ltd.; Honoraria (self): Care Net, Inc; Honoraria (self): Reno. Medical K.K.; Honoraria (self), Advisory/Consultancy: Kyorin Pharmaceutical Co., Ltd.; Honoraria (self): Medical Review Co., Ltd.; Honoraria (self): Roche Diagnostics K.K.; Honoraria (self), Research grant/Funding (institution): Bayer Yakuhin, Ltd; Honoraria (self): Medical Mobile Communications Co., Ltd; Honoraria (self): 3H Clinical Trial Inc.; Honoraria (self): Nichi-Iko Pharmaceutical Co., Ltd.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Takeda Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): Taiho Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): SymBio Pharmaceuticals Limited; Honoraria (self): Nanzando Co., Ltd.; Honoraria (self): Yodosha Co., Ltd.; Honoraria (self): Nikkei Business Publications, Inc; Honoraria (self): Thermo Fisher Scientific K.K.; Honoraria (self): Yomiuri Telecasting Corporation; Honoraria (self): Nippon Kayaku Co., Ltd.; Honoraria (self), Research grant/Funding (institution): AbbVie Inc.; Research grant/Funding (institution): inVentiv Health Japan; Research grant/Funding (institution): Icon Japan K.K.; Research grant/Funding (institution): Gritsone Oncology.Inc; Research grant/Funding (institution): PAREXEL International Corp.; Research grant/Funding (institution): Kissei Pharmaceutical Co., Ltd.; Research grant/Funding (institution): EPS Corporation.; Research grant/Funding (institution): Syneos Health; Research grant/Funding (institution): Pfizer R&D Japan G.K.; Research grant/Funding (institution): A2 Healthcare Corp.; Research grant/Funding (institution): Quintiles Inc. / IQVIA Services Japan K.K.; Research grant/Funding (institution): EP-CRSU Co., Ltd.; Research grant/Funding (institution): Linical Co.,Ltd.; Research grant/Funding (institution): Eisai Co., Ltd.; Research grant/Funding (institution): CMIC Shift Zero K.K.; Research grant/Funding (institution): Kyowa Hakko Kirin Co.,Ltd; Research grant/Funding (institution): EPS International Co., Ltd.; Research grant/Funding (institution): Otsuka Pharmaceutical Co., Ltd.; Honoraria (self), Research grant/Funding (institution): AstraZeneca K.K.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.